Can risk of sarcopenia predict poorer quality of life in hemodialysis patients?

Sâmia Marques Lourenço Landim; Paulo Roberto Santos; Kailane Martins Cardoso; Luciana Abreu Sousa; Victor Lavinas Santos

doi:10.1590/SciELOPreprints.3352

article.authors6a179f230606e

Sâmia Marques Lourenço Landim Universidade Federal do Ceará https://orcid.org/0000-0001-5983-557X
Paulo Roberto Santos Universidade Federal do Ceará https://orcid.org/0000-0002-3092-4808
Kailane Martins Cardoso Universidade Federal do Ceará https://orcid.org/0000-0002-7463-8600
Luciana Abreu Sousa Universidade Federal do Ceará
Victor Lavinas Santos Universidade de Fortaleza https://orcid.org/0000-0002-3151-5221

DOI:

https://doi.org/10.1590/SciELOPreprints.3352

Keywords:

Chronic Kidney Failure, Hemodialysis, Quality of Life, Sarcopenia

Resumen

Background: Sarcopenia and low quality of life (QOL) are widely found among hemodialysis (HD) patients. We aimed to verify whether risk of sarcopenia can predict QOL level in patients submitted to HD.

Methods: The sample was formed by 147 chronic kidney disease patients undergoing HD in October 2020 at a single dialysis center. Demographic and clinical data were collected. Risk of sarcopenia was classified using the SARC-F questionnaire. QOL was evaluated by the Brazilian version of the SF-36. QOL scores were compared between patients with and without risk of sarcopenia. Multivariate linear regression was performed to test risk of sarcopenia as an independent predictor of QOL scores.

Results: There were 62 (42.2%) patients classified as having risk of sarcopenia. In the comparison of QOL scores between patients with and without risk of sarcopenia, scores of seven dimensions were significantly lower among patients with sarcopenia risk, the only exception being role-emotional. Risk of sarcopenia was an independent predictor of six dimensions of QOL, except for role-emotional and mental health.

Conclusion: We found risk of sarcopenia to be an independent predictor of QOL among HD patients. Our results point to the possibility of improving patients’ QOL by intervening to minimize the risk of sarcopenia.